A kayak challenge is being launched to raise funds for a homelessness charity. Pete Miller, managing director of Miller Installations who lives in North Norfolk, will take on a 100-mile solo journey ...
Background Disease-modifying therapies (DMTs) for Alzheimer’s disease (AD) have early evidence of efficacy. Widespread delivery of DMTs will require major service reconfiguration. Treatment pathways ...
Amyloid-targeted monoclonal antibodies are the first disease-modifying therapies (DMTs) approved for Alzhemier’s disease (AD). Aducanumab received accelerated approval by the FDA but was not fully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results